SEARCH:   Advanced

Blood, 1 February 2008, Vol. 111, No. 3, pp. 1078-1084. Prepublished online as a Blood First Edition Paper on November 1, 2007; DOI 10.1182/blood-2007-07-099978. This Article Full Text (PDF) Supplemental Appendix All Versions of this Article: blood-2007-07-099978v1 111/3/1078    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Ades, L. Articles by Fenaux, P. Search for Related Content PubMed PubMed Citation Articles by Ades, L. Articles by Fenaux, P. Social Bookmarking                   What's this?  Previous Article  |  Next Article  Submitted July 10, 2007 Accepted October 17, 2007 Treatment of newly diagnosed acute promyelocytic leukemia (APL): a comparison of French-Belgian-Swiss and PETHEMA results Lionel Ades, Miguel A. Sanz, Sylvie Chevret, Pau Montesinos, Patrice Chevallier, Emmanuel Raffoux, Edo Vellenga, Agnes Guerci, Arnaud Pigneux, Francoise Huguet, Consuelo Rayon, Anne Marie Stoppa, Javier de la Serna, Jean-Yves Cahn, Sandrine Meyer-Monard, Thomas Pabst, Xavier Thomas, Stephane de Botton, Ricardo Parody, Juan Bergua, Thierry Lamy, Anne Vekhoff, Silvia Negri, Norbert Ifrah, Herve Dombret, Augustin Ferrant, Dominique Bron, Laurent Degos, and Pierre Fenaux* Hopital Avicenne, Universite Paris 13, Bobigny, France University Hospital La Fe, Valencia, Spain Hopital Saint Louis, Universite Paris 7, Paris, France CHU Nantes, Nantes, France University Hospital Groningen, Hanzeplein, Netherlands CHU Nancy, Nancy, France CHU de Bordeaux, Bordeaux, France CHU de Toulouse, Toulouse, France Hospital Central de Asturias, Oviedo, Spain Institut Paoli Calmettes, Marseille, France Hospital 12 de Octubre, Madrid, Spain CHU Grenoble, Grenoble, France Universitatsspital Basel, Basel, Switzerland Universitatsspital Berne, Berne, Switzerland CHU Lyon, Lyon, France Institut Gustave Roussy, Villejuif, France Hospital Virgen del Rocio, Sevilla, Spain Hospital San Pedro de Alcantara, Caceres, Spain CHU Rennes, Rennes, France Hotel Dieu, Universite Paris 5, Paris, France Hospital Carlos Haya, Malaga, Spain CHU Angers, Angers, France Universite Catholique de Louvain, Brussels, Belgium Institut Jules Bordet, Brussels, Belgium * Corresponding author; email: pierre.fenaux{at}avc.aphp.fr. ATRA plus anthracycline chemotherapy is the reference treatment of newly diagnosed APL, while the role of AraC remains disputed. We performed a joint analysis of patients <65 years included in PETHEMA LPA99 trial, where patients received no AraC in addition to ATRA, high cumulative dose idarubicin and mitoxan-trone, and APL 2000 trial where patients received AraC in addition to ATRA and lower cumulative dose daunorubicin. Maintenance treatment was the same in both studies. In patients with WBC <10 x 109/l, CR rates were similar, but 3 year cumulative incidence of relapse (CIR), and median days spent in hospital significantly lower in LPA 99 trial: 4.2% vs 14.3%, (p=0.03,) and 50 vs 72 days (p<0.001), respectively, although 3 year survival was similar in both trials. This suggested that AraC is not required in APL with WBC< 10 x 109/l, at least in trials with high dose anthracycline and maintenance treatment. In patients with WBC10 x 109/l), however, the CR rate (95.1% vs 83.6% P=0.018) and 3 year survival (91.5% vs 80.8%, P=0.026) were significantly higher in APL 2000 trial and there was a trend for lower 3 year CIR (9.9% vs 18.5%, P=0.12), suggesting a beneficial role for AraC in those patients. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: C. Kelaidi, S. Chevret, S. De Botton, E. Raffoux, A. Guerci, X. Thomas, A. Pigneux, T. Lamy, F. Rigal-Huguet, S. Meyer-Monard, et al. Improved Outcome of Acute Promyelocytic Leukemia With High WBC Counts Over the Last 15 Years: The European APL Group Experience J. Clin. Oncol., June 1, 2009; 27(16): 2668 - 2676. [Abstract] [Full Text] [PDF] M. A. Sanz, D. Grimwade, M. S. Tallman, B. Lowenberg, P. Fenaux, E. H. Estey, T. Naoe, E. Lengfelder, T. Buchner, H. Dohner, et al. Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet Blood, February 26, 2009; 113(9): 1875 - 1891. [Abstract] [Full Text] [PDF] C. Santamaria, M. C. Chillon, R. Garcia-Sanz, A. Balanzategui, M. E. Sarasquete, M. Alcoceba, F. Ramos, T. Bernal, J. A. Queizan, M. J. Penarrubia, et al. The relevance of preferentially expressed antigen of melanoma (PRAME) as a marker of disease activity and prognosis in acute promyelocytic leukemia Haematologica, December 1, 2008; 93(12): 1797 - 1805. [Abstract] [Full Text] [PDF] W.-Y. Au, S. Tam, B. M. Fong, and Y.-L. Kwong Determinants of cerebrospinal fluid arsenic concentration in patients with acute promyelocytic leukemia on oral arsenic trioxide therapy Blood, November 1, 2008; 112(9): 3587 - 3590. [Abstract] [Full Text] [PDF] M. Ono, T. Watanabe, C. Shimizu, N. Hiramoto, Y. Goto, K. Yonemori, T. Kouno, M. Ando, K. Tamura, N. Katsumata, et al. Therapy-Related Acute Promyelocytic Leukemia Caused by Hormonal Therapy and Radiation in a Patient with Recurrent Breast Cancer Jpn. J. Clin. Oncol., August 1, 2008; 38(8): 567 - 570. [Abstract] [Full Text] [PDF] M. S. Tallman and J. K. Altman Curative Strategies in Acute Promyelocytic Leukemia Hematology, January 1, 2008; 2008(1): 391 - 399. [Abstract] [Full Text] [PDF]

	Copyright © 2007 by American Society of Hematology         Online ISSN: 1528-0020